Changing the landscape in
Life-Threatening Diseases

^aDiabetic peripheral neuropathic pain (DPNP). ^bChronic Kidney Disease (CKD). ^cBardoxolone methyl (bardoxolone). On February 25, 2022, we received a Complete Response Letter from the Food and Drug Administration (FDA). We will continue to work with the FDA to confirm our next steps on our Alport syndrome program. Marketing Authorisation Application in Europe is under review. ^dAutosomal Dominant Polycystic Kidney Disease (ADPKD). ^eAYAME study conducted in Japan by our strategic collaborator in CKD, Kyowa Kirin.

Omaveloxolone, bardoxolone methyl, and RTA 901 are investigational drugs. Safety and efficacy have not been established by any agency.